Mainz Biomed to Present Results of Pancreatic Cancer Verification Study at AACR 2026 Annual Meeting

Core Insights - Mainz Biomed N.V. is set to present its blood-based mRNA signature for pancreatic ductal adenocarcinoma (PDAC) detection and differentiation from intraductal papillary mucinous neoplasms (IPMN) at the AACR 2026 Annual Meeting in San Diego from April 17 to 22, 2026 [1][3] - The company will showcase results from a verification study involving a proprietary combination of blood-derived mRNA biomarkers and AI-assisted modeling, tested on a cohort of 30 subjects [2] - The aim of this study is to revolutionize pancreatic cancer screening practices and contribute to reducing cancer mortality rates globally [3] Company Overview - Mainz Biomed specializes in developing molecular genetic diagnostic solutions for life-threatening conditions, with its flagship product being ColoAlert, a non-invasive early-detection test for colorectal cancer marketed in Europe [4] - The company is currently conducting the eAArly DETECT 2 clinical study in preparation for a pivotal FDA study for regulatory approval in the U.S. [4] - Additionally, Mainz Biomed is developing PancAlert, an early-stage pancreatic cancer screening test utilizing real-time PCR multiplex detection of molecular-genetic biomarkers in blood and stool samples [4]